J 2019

Significance of postoperative follow-up of patients with metastatic colorectal cancer using circulating tumor DNA

BENESOVA, Lucie, Tereza HALKOVA, Renata PTACKOVA, Anastasiya SEMYAKINA, Katerina MENCLOVA et. al.

Basic information

Original name

Significance of postoperative follow-up of patients with metastatic colorectal cancer using circulating tumor DNA

Authors

BENESOVA, Lucie (203 Czech Republic, guarantor), Tereza HALKOVA (203 Czech Republic), Renata PTACKOVA (203 Czech Republic), Anastasiya SEMYAKINA (203 Czech Republic), Katerina MENCLOVA (203 Czech Republic), Jiri PUDIL (203 Czech Republic), Miroslav RYSKA (203 Czech Republic), Miroslav LEVY (203 Czech Republic), Jaromir SIMSA (203 Czech Republic), Filip PAZDIREK (203 Czech Republic), Jiri HOCH (203 Czech Republic), Milan BLAHA (203 Czech Republic, belonging to the institution) and Marek MINARIK (203 Czech Republic)

Edition

World Journal of Gastroenterology, Baishideng, 2019, 1007-9327

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30219 Gastroenterology and hepatology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 3.665

RIV identification code

RIV/00216224:14110/19:00108601

Organization unit

Faculty of Medicine

UT WoS

000511328600007

Keywords in English

Circulating tumor DNA; Metastatic colorectal cancer; Postoperative; Radicality of resection; Follow-up; Recurrence

Tags

Tags

International impact, Reviewed
Změněno: 19/2/2020 10:37, Mgr. Tereza Miškechová

Abstract

V originále

BACKGROUND One of the most notable applications for circulating tumor DNA (ctDNA) detection in peripheral blood of patients with metastatic colorectal cancer (mCRC) is a long-term postoperative follow-up. Sometimes referred to as a "liquid (re)biopsy" it is a minimally invasive procedure and can be performed repeatedly at relatively short intervals (months or even weeks). The presence of the disease and the actual extent of the tumor burden (tumor mass) within the patient's body can be monitored. This is of particular importance, especially when evaluating radicality of surgical treatment as well as for early detection of disease progression or recurrence. AIM To confirm the radicality of surgery using ctDNA and compare available methods for detection of recurrence in metastatic colorectal cancer. METHODS A total of 47 patients with detected ctDNA and indications for resection of mCRC were enrolled in the multicenter study involving three surgical centers. Standard postoperative follow-ups using imaging techniques and the determination of tumor markers were supplemented by ctDNA sampling. In addition to the baseline ctDNA testing prior to surgery, a postoperative observation was conducted by evaluating ctDNA presence up to a week after surgery and subsequently at approximately three-month intervals. The presence of ctDNA was correlated with radicality of surgical treatment and the actual clinical status of the patient. RESULTS Among the monitored patients, the R0 (curative) resection correlated with postoperative ctDNA negativity in 26 out of 28 cases of surgical procedures (26/28, 93%). In the remaining cases of R0 surgeries that displayed ctDNA, both patients were diagnosed with a recurrence of the disease after 6 months. In 7 patients who underwent an R1 resection, 4 ctDNA positivities (4/7, 57%) were detected after surgery and associated with the confirmation of early disease recurrence (after 3 to 7 months). All 15 patients (15/15, 100%) undergoing R2 resection remained constantly ctDNA positive during the entire follow-up period. In 22 cases of recurrence, ctDNA positivity was detected 22 times (22/22, 100%) compared to 16 positives (16/22, 73%) by imaging methods and 15 cases (15/22, 68%) of elevated tumor markers. CONCLUSION ctDNA detection in patients with mCRC is a viable tool for early detection of disease recurrence as well as for confirmation of the radicality of surgical treatment.

Links

NV15-27939A, research and development project
Name: Přínos nové technologie „liquid biopsy“ pro monitoraci komplexní léčby kolorektálního karcinomu ve 3.- 4. stádiu onemocnění